TABLE 2

Baseline characteristics of subjects divided by outcome

NGTDeveloped/remained IGTDeveloped type 2 diabetes
NGT at baseline
N792334568
 Sex (M, F)450, 342136, 198207, 361
 Follow-up (years)15.5 ± 0.414.9 ± 0.5*16.8 ± 0.4*,
 Age (years)18.3 ± 0.624.3 ± 1.1*22.4 ± 0.6*
 BMI (kg/m2)21.8 ± 0.223.9 ± 0.4*26.9 ± 0.3*,
 2-h glucose (mg/dl)  99 ± 0.6 104 ± 1.1* 106 ± 0.8*
 Gamma globulin (g/100 ml)1.14 (1.132–1.146)1.16 (1.153–1.177)*1.19 (1.183–1.202)*,
IGT at baseline
N3927127
 Sex (M, F)23, 1610, 1743, 84
 Follow-up (years)11.7 ± 1.610.5 ± 1.6 8.7 ± 0.7
 Age (years)38.5 ± 4.344.6 ± 4.533.8 ± 1.4
 BMI (kg/m2)27.3 ± 1.029.4 ± 1.4*32.0 ± 0.6*
 2-h glucose (mg/dl) 157 ± 1.9 159 ± 3.6 158 ± 1.4
 Gamma globulin (g/100 ml)1.18 (1.149–1.218)1.15 (1.085–1.214)1.25 (1.232–1.274)
  • Characteristics of 1,887 Pima subjects who had either NGT (n = 1,694) or IGT (n = 193) at baseline and in whom at least one follow-up examination was available. Data are means ± SE with the exception of gamma globulin (geometric mean [range of ± 1 SE]). In those with IGT at baseline, ANOVA was in keeping with significant differences among groups for age (P < 0.05) and BMI (P < 0.0005) after adjustment for sex. In those with NGT at baseline, ANOVA was in keeping with significant differences among groups for age, BMI, 2-h glucose and gamma globulin (P < 0.0005) and follow-up time (P < 0.05) after adjustment for sex.

  • *

    * P < 0.05 vs. NGT (Student-Newman-Keuls);

  • P < 0.05 for type 2 diabetic group vs. IGT (Student-Newman-Keuls).